Show simple item record

dc.contributor.authorCygankiewicz, Adamen
dc.date.accessioned2015-06-17T08:35:24Z
dc.date.available2015-06-17T08:35:24Z
dc.date.issued2011-03-04en
dc.identifier.issn1730-2366
dc.identifier.urihttp://hdl.handle.net/11089/9867
dc.description.abstractSeven-transmembrane (7TM) receptors are one of the most important proteins involved in perception of extracellular stimuli and regulation of variety of intracellular signaling pathways. Divergence of receptor types, their ligands and signaling pathways makes 7TM receptors important factors in pathology of many diseases. This review focused on the main diseases in which involvement of 7TM receptors was established e.g., retinitis pigmentosa, severe obesity, and dwarfism. Recent findings of aberrant expression of 7TM receptors in development of cancer were also summarized.en
dc.publisherWydawnictwo Uniwersytetu Łódzkiegoen
dc.relation.ispartofseriesFolia Biologica et Oecologica;6en
dc.rightsThis content is open access.en
dc.subjectSeven-transmembrane receptorsen
dc.subjectG protein coupled receptorsen
dc.subjectpathologyen
dc.subjectcanceren
dc.titlePhysiopathological Implications of 7TM Receptorsen
dc.page.number33-47en
dc.contributor.authorAffiliationDepartment of Cytobiochemistry, University of Łódź, Pomorska 141/143, 90-236 Łódź, Polanden
dc.referencesAbdulaev, N. G. 2003. Building a stage for interhelical play in rhodopsin. Trends Biochem. Sci. 28: 399-402.12932725 doi: 10.1016/S0968-0004(03)00164-6en
dc.referencesArora, P., Ricks, T. K., Trejo, J. 2007. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J. Cell Sci. 120: 921-928.17344429 doi: 10.1242/jcs.03409en
dc.referencesBalistreri, C. R., Caruso, C., Grimaldi, M. P., Listi, F., Vasto, S., Orlando, V., Campagna, A. M., Lio, D., Candore, G. 2007. CCR5 receptor: biologic and genetic implications in age-related diseases. Ann. N. Y. Acad. Sci. 1100: 162-172.en
dc.referencesBarak, L. S., Oakley, R. H., Laporte, S. A., Caron, M. G. 2001. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc. Natl. Acad. Sci. U. S. A 98: 93-98. doi: 10.1073/pnas.98.1.93en
dc.referencesBarzon, L., Pacenti, M., Masi, G., Stefani, A. L., Fincati, K., Palu, G. 2005. Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors. Oncology 68: 414-421.en
dc.referencesBiebermann, H., Krude, H., Elsner, A., Chubanov, V., Gudermann, T., Gruters, A. 2003. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 52: 2984-2988. doi: 10.2337/diabetes.52.12.2984en
dc.referencesBourne, H. R., Sanders, D. A., McCormick, F. 1991. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349: 117-127.en
dc.referencesButler, A. A., Kesterson, R. A., Khong, K., Cullen, M. J., Pelleymounter, M. A., Dekoning, J., Baetscher, M., Cone, R. D. 2000. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141: 3518-3521.en
dc.referencesCadet, P., Mantione, K. J., Stefano, G. B. 2003. Molecular identification and functional expression of mu 3, a novel alternatively spliced variant of the human mu opiate receptor gene. J. Immunol. 170: 5118-5123.en
dc.referencesChen, A. S., Marsh, D. J., Trumbauer, M. E., Frazier, E. G., Guan, X. M., Yu, H., Rosenblum, C. I., Vongs, A., Feng, Y., Cao, L., Metzger, J. M., Strack, A. M., Camacho, R. E., Mellin, T. N., Nunes, C. N., Min, W., Fisher, J., Gopal-Truter, S., MacIntyre, D. E., Chen, H. Y., Van der Ploeg, L. H. 2000. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26: 97-102.en
dc.referencesde Keyzer, Y., Rene, P., Beldjord, C., Lenne, F., Bertagna, X. 1998. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin. Endocrinol. (Oxf) 49: 475-482. doi: 10.1046/j.1365-2265.1998.00560.xen
dc.referencesEaveri, R., Ben-Yehudah, A., Lorberboum-Galski, H. 2004. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr. Cancer Drug Targets. 4: 673-687.en
dc.referencesFilardo, E. J., Graeber, C. T., Quinn, J. A., Resnick, M. B., Giri, D., DeLellis, R. A., Steinhoff, M. M., Sabo, E. 2006. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12: 6359-6366.en
dc.referencesFuessel, S., Weigle, B., Schmidt, U., Baretton, G., Koch, R., Bachmann, M., Rieber, E. P., Wirth, M. P., Meye, A. 2006. Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs. Cancer Lett. 236: 95-104.en
dc.referencesGao, Y., Kitagawa, K., Hiramatsu, Y., Kikuchi, H., Isobe, T., Shimada, M., Uchida, C., Hattori, T., Oda, T., Nakayama, K., Nakayama, K. I., Tanaka, T., Konno, H., Kitagawa, M. 2006. Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res. 66: 11623-11631. doi: 10.1158/0008-5472.CAN-06-2629en
dc.referencesGovaerts, C., Srinivasan, S., Shapiro, A., Zhang, S., Picard, F., Clement, K., Lubrano-Berthelier, C., Vaisse, C. 2005. Obesity-associated mutations in the melanocortin 4 receptor provide novel insights into its function. Peptides 26: 909-1919.en
dc.referencesGranovsky-Grisaru, S., Zaidoun, S., Grisaru, D., Yekel, Y., Prus, D., Beller, U., Bar-Shavit, R. 2006. The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol. Oncol. 103: 802-806. doi: 10.1016/j.ygyno.2006.05.048en
dc.referencesGugger, M., White, R., Song, S., Waser, B., Cescato, R., Riviere, P., Reubi, J. C. 2008. GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis. Markers 24: 41-50. doi: 10.1155/2008/857474en
dc.referencesHata, K., Dhar, D. K., Watanabe, Y., Nakai, H., Hoshiai, H. 2007. Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer. Eur. J. Cancer 43 (9): 1452-1459. doi: 10.1016/j.ejca.2007.03.004en
dc.referencesHirasawa, A., Shibata, K., Horie, K., Takei, Y., Obika, K., Tanaka, T., Muramoto, N., Takagaki, K., Yano, J., Tsujimoto, G. 1995. Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett. 363: 56-260.en
dc.referencesHopkins, A. L., Groom, C. R. 2002. The druggable genome. Nat. Rev. Drug Discov. 1: 727-730.12209152 doi: 10.1038/nrd892en
dc.referencesHuang, Y., Fan, J., Yang, J., Zhu, G. Z. 2007. Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells. Mol. Cell Biochem. 308: 133-139.en
dc.referencesJorda M. A., Rayman, N., Tas, M., Verbakel, S. E., Battista, N., van, L. K., Lowenberg, B., Maccarrone, M., Delwel, R. 2004. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104: 526-534. doi: 10.1182/blood-2003-12-4357en
dc.referencesKitayama, J., Shida, D., Sako, A., Ishikawa, M., Hama, K., Aoki, J., Arai, H., Nagawa, H. 2004. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6: R640-R646. doi: 10.1186/bcr935en
dc.referencesKorner, M., Hayes, G. M., Rehmann, R., Zimmermann, A., Friess, H., Miller, L. J., Reubi, J. C. 2005. Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am. J. Pathol. 167: 959-968.en
dc.referencesKuo, W. H., Chang, L. Y., Liu, D. L., Hwa, H. L., Lin, J. J., Lee, P. H., Chen, C. N., Lien, H. C., Yuan, R. H., Shun, C. T., Chang, K. J., Hsieh, F. J. 2007. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan. J. Obstet. Gynecol. 46: 135-145. doi: 10.1016/S1028-4559(07)60007-2en
dc.referencesLagerstrom, M. C., Schioth, H. B. 2008. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7: 339-357.18382464 doi: 10.1038/nrd2518en
dc.referencesLee, Y. S., Poh, L. K., Loke, K. Y. 2002. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J. Clin. Endocrinol. Metab 87 (3): 1423-1426.en
dc.referencesLi, S., Huang, S., Peng, S. B. 2005. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol. 27: 1329-1339.16211229en
dc.referencesLin-Su, K., Wajnrajch, M. P. 2002. Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor. Rev. Endocr. Metab Disord. 3: 313-323. doi: 10.1023/A:1020949507265en
dc.referencesMagnusson, C., Ehrnstrom, R., Olsen, J., Sjolander, A. 2007. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res. 67: 9190-9198.17909024 doi: 10.1158/0008-5472.CAN-07-0771en
dc.referencesMayo, K. E., Hammer, R. E., Swanson, L. W., Brinster, R. L., Rosenfeld, M. G., Evans, R. M. 1988. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol. Endocrinol. 2: 606-612.3137455 doi: 10.1210/mend-2-7-606en
dc.referencesMazzuco, T. L., Chabre, O., Feige, J. J., Thomas, M. 2007. Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol. Cell Endocrinol. 265-266: 23-28.en
dc.referencesMcClanahan, T., Koseoglu, S., Smith, K., Grein, J., Gustafson, E., Black, S., Kirschmeier, P., Samatar, A. A. 2006. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol. Ther. 5: 419-426. doi: 10.4161/cbt.5.4.2521en
dc.referencesMerle, P., Kim, M., Herrmann, M., Gupte, A., Lefrancois, L., Califano, S., Trepo, C., Tanaka, S., Vitvitski, L., de la, Monte S., Wands, J. R. 2005. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J. Hepatol. 43: 854-862. doi: 10.1016/j.jhep.2005.05.018en
dc.referencesNelson, C. P., Challiss, R. A. 2007. "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol. 73: 737-751.17046719 doi: 10.1016/j.bcp.2006.09.005en
dc.referencesNicolle, G., Comperat, E., Nicolaiew, N., Cancel-Tassin, G., Cussenot, O. 2007. Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression in transitional cell carcinoma of the bladder. Ann. Oncol. 18: 605-607.en
dc.referencesParmigiani, R. B., Magalhaes, G. S., Galante, P. A., Manzini, C. V., Camargo, A. A., Malnic, B. 2004. A novel human G protein-coupled receptor is over-expressed in prostate cancer. Genet. Mol. Res. 3: 521-531.en
dc.referencesPierce, K. L., Luttrell, L. M., Lefkowitz, R. J. 2001. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20: 1532-1539.11313899 doi: 10.1038/sj.onc.1204184en
dc.referencesPierce, K. L., Premont, R. T., Lefkowitz, R. J. 2002. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3: 639-650.12209124 doi: 10.1038/nrm908en
dc.referencesRached, M., Buronfosse, A., Begeot, M., Penhoat, A. 2004. Inactivation and intracellular retention of the human I183N mutated melanocortin 3 receptor associated with obesity. Biochim. Biophys. Acta 1689: 229-234.en
dc.referencesRingel, M. D., Hardy, E., Bernet, V. J., Burch, H. B., Schuppert, F., Burman, K. D., Saji, M. 2002. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J. Clin. Endocrinol. Metab 87: 2399. doi: 10.1210/jcem.87.5.8626en
dc.referencesSanchez-Laorden, B. L., Jimenez-Cervantes, C., Garcia-Borron, J. C. 2007. Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer. J. Biol. Chem. 282: 3241-3251.en
dc.referencesSchlyer, S., Horuk, R. 2006. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov. Today 11: 481-493. doi: 10.1016/j.drudis.2006.04.008en
dc.referencesSchoneberg, T., Schulz, A., Biebermann, H., Hermsdorf, T., Rompler, H., Sangkuhl, K. 2004. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol. Ther. 104: 173-206.15556674 doi: 10.1016/j.pharmthera.2004.08.008en
dc.referencesShashidhar, S., Lorente, G., Nagavarapu, U., Nelson, A., Kuo, J., Cummins, J., Nikolich, K., Urfer, R., Foehr, E. D. 2005. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 24: 1673-1682. doi: 10.1038/sj.onc.1208395en
dc.referencesSodhi, A., Montaner, S., Gutkind, J. S. 2004. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? FASEB J. 18: 422-427. doi: 10.1096/fj.03-1035hypen
dc.referencesSpiegel, A. M. 1997. Inborn errors of signal transduction: mutations in G proteins and G protein-coupled receptors as a cause of disease. J. Inherit. Metab Dis. 20: 113-121. doi: 10.1023/A:1005393501786en
dc.referencesSpiegel, A. M. 2000. G protein defects in signal transduction. Horm. Res. 53: 17-22.10971097 doi: 10.1159/000023526en
dc.referencesSpiegel, A. M., Weinstein, L. S. 2004. Inherited diseases involving g proteins and g protein-coupled receptors. Annu. Rev. Med. 55: 27-39. doi: 10.1146/annurev.med.55.091902.103843en
dc.referencesStojanovic, A., Hwa, J. 2002. Rhodopsin and retinitis pigmentosa: shedding light on structure and function. Receptors. Channels 8: 33-50.12402507 doi: 10.1080/10606820212137en
dc.referencesTao, Y. X. 2005. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol. Cell Endocrinol. 239: 1-14.en
dc.referencesTao, Y. X. 2006. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol. Ther. 111: 949-973.16616374 doi: 10.1016/j.pharmthera.2006.02.008en
dc.referencesTao, Y. X., Segaloff, D. L. 2004. Functional characterization of melanocortin-3 receptor variants identify a loss-of-function mutation involving an amino acid critical for G protein-coupled receptor activation. J. Clin. Endocrinol. Metab 89: 3936-3942. doi: 10.1210/jc.2004-0367en
dc.referencesVischer, H. F., Leurs, R., Smit, M. J. 2006. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol. Sci. 27: 56-63.16352349 doi: 10.1016/j.tips.2005.11.006en
dc.referencesWilson, S., Bergsma, D. J., Chambers, J. K., Muir, A. I., Fantom, K. G., Ellis, C., Murdock, P. R., Herrity, N. C., Stadel, J. M. 1998. Orphan G-protein-coupled receptors: the next generation of drug targets? Br. J. Pharmacol. 125: 1387-1392.en
dc.referencesYang, M., Zhong, W. W., Srivastava, N., Slavin, A., Yang, J., Hoey, T., An, S. 2005. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc. Natl. Acad. Sci. U. S. A 102: 6027-6032. doi: 10.1073/pnas.0501535102en
dc.identifier.doi10.2478/v10107-009-0005-2en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record